Obsidian Therapeutics Inc.

NASDAQ: OBX · Healthcare · Biotechnology

PublicHQ Cambridge, MA · MiddlesexCIK 0002130606Reports USD

#1 of 1,422 Healthcare companies by revenue

EA Score

——

FH —DQ —GM —SS 22

v0.1 · 5/100 weight · pillars only

↑ market scale, filing timeliness · ↓ listing tenure, workforce scale

Methodology →

Revenue TTM

—

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

—

Employees

as of 2026-08-18

Market cap

$35.4M

as of 2026-08-18

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

No filed financials — private or non-XBRL filer.

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Obsidian Therapeutics Inc.’s financial profile?

Obsidian Therapeutics Inc. has no structured financials on file — private or non-XBRL filer.

Peers · Healthcare

Rocket Doctor AI Inc.——BetterLife Pharma Inc.——BriaCell Therapeutics Corp.——MIRA Pharmaceuticals, Inc.——Lantern Pharma Inc.——Estrella Immunopharma, Inc.——

Neighbors

Middlesex →

GE Vernova Inc.$38.1B63C Thermo Fisher Scientific Inc.$44.6B86A Analog Devices, Inc.$11.0B87A The TJX Companies, Inc.$60.4B85A Boston Scientific Corporation$20.1B88A Symbotic Inc.$2.2B49D

Key facts

CEOMadan Jagasia

SectorHealthcare

IndustryBiotechnology

HeadquartersCambridge, MA

ExchangeNASDAQ: OBX

Employees3

IPO date2026-08-04

Latest filings

10-Q2026-08-14 8-K2026-08-03

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.